← Back to Search

Neurotoxin

Botox for Compartment Syndrome

Phase 4
Waitlist Available
Led By Michael Suer, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 months, 4 months, 6 months
Awards & highlights

Study Summary

This trial will test whether botox injections can relieve pain for people with a chronic condition called recurrent compartment syndrome.

Eligible Conditions
  • Compartment Syndrome of the Leg

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 months, 4 months, 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 months, 4 months, 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Pain Score
Incidence of Adverse Events
Number of Participants with Lower Extremity Weakness
Secondary outcome measures
Change in ability to perform activities of daily living
Change in ankle dorsiflexion strength using Kiio Force Sensor
Change in ankle eversion strength using Kiio Force Sensor
+9 more

Side effects data

From 2010 Phase 4 trial • 33 Patients • NCT00178646
8%
Foot pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Low Volume, High Dose
High Volume, High Dose
Low Volume, Low Dose

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with R-CECSExperimental Treatment1 Intervention
Botox to be injected under standard palpatory technique into the affected lower leg compartment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Botox
2014
Completed Phase 4
~1180

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,193 Previous Clinical Trials
3,161,938 Total Patients Enrolled
Michael Suer, MDPrincipal InvestigatorUniversity of Wisconsin, Madison
1 Previous Clinical Trials
7 Total Patients Enrolled
~0 spots leftby Jun 2025